Swiss Life Sciences Stock News

In March 2026, Emmi AG was removed from the FTSE All-World Index, altering its representation in a widely followed global equity benchmark. This index removal may influence how index-tracking institutional investors allocate capital to Emmi, potentially reshaping its visibility in global portfolios. Next, we will examine how Emmi's removal from the FTSE All-World Index may influence its investment narrative and investor perception. Capitalize on the AI infrastructure supercycle with our...

SoftwareOne Holding (SWX:SWON) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 486.6 million and basic EPS of CHF 0.07, while the trailing twelve months show revenue of CHF 1.2 billion and basic EPS of CHF 0.13. Over the past reported periods, revenue has moved from CHF 529.2 million and EPS of CHF 0.18 in the first half of 2024 to CHF 486.2 million and an EPS loss of CHF 0.19 in the second half of 2024, before landing at the latest CHF 486.6 million and CHF...

Swissquote Group Holding SA has released its full-year 2025 results, reporting net income of CHF 366.39 million and basic earnings per share from continuing operations of CHF 24.49, alongside declaring an annual dividend of CHF 7.40 per share payable in May 2026. The combination of higher earnings and a larger cash payout suggests management is comfortable sharing more of the company’s profitability with shareholders. We’ll now explore how Swissquote’s strong 2025 earnings and increased CHF...

Why Idorsia’s latest pediatric insomnia data matters for shareholders Idorsia (SWX:IDIA) shares have moved after the company reported positive top-line Phase 2 results for daridorexant in children with insomnia disorder, including patients with neurodevelopmental conditions, and outlined plans to engage regulators on next steps. The trial used a 2 week treatment period and showed a statistically significant, dose-dependent improvement in total sleep time from baseline on Day 1, along with...

Julius Bär Gruppe (SWX:BAER) has drawn attention after announcing plans to redeem its USD 350 million Perpetual Tier 1 subordinated bonds at par plus accrued interest on the first call date in April 2026. See our latest analysis for Julius Bär Gruppe. The refinancing decision comes after a period where the share price has softened, with a 30 day share price return of a 12.04% decline and a year to date share price return of a 12.28% decline. Longer term total shareholder returns over three...

Novartis (SWX:NOVN) agreed to acquire Excellergy, a biotech focused on anti IgE therapies for allergic diseases, including food allergies. The company reported positive final two year Phase III results for Fabhalta in IgA nephropathy, indicating slower kidney function decline in the study population. The FDA granted Fabhalta priority review for traditional approval in IgA nephropathy. For investors watching large pharma, Novartis sits at the intersection of immunology, allergy, and kidney...

The recent U.S. District Court order upholding a jury finding that Alcon (SWX:ALC) willfully infringed three Sight Sciences patents puts fresh attention on potential legal liabilities, ongoing Hydrus Microstent royalties, and appeal risk. See our latest analysis for Alcon. At a share price of CHF59.4, Alcon has a 1 day share price return of 0.58% and a 7 day share price return of 1.85%. However, a 1 year total shareholder return of 28.37% decline shows sentiment has cooled despite earlier...

PolyPeptide Group (SWX:PPGN) has expanded its credit facility to €200 million, bringing ING Bank into its lending group alongside UBS, Danske Bank and Zürcher Kantonalbank to support its revenue and capacity expansion objectives. See our latest analysis for PolyPeptide Group. That credit facility news arrives as momentum has been picking up, with the 7 day share price return of 8.54% and year to date share price return of 11.25% feeding into a 1 year total shareholder return of 62.61%. The...

If you are wondering whether UBS Group's current share price reflects its true value, focusing on what the numbers say rather than the headlines can help clarify the picture. The stock recently closed at CHF 29.38, with returns of 12.9% over 1 year and 70.6% over 3 years, alongside a 23.0% decline year to date and an 8.2% decline over the last 30 days. These moves may signal shifting expectations or risk perceptions. Recent coverage around UBS Group has highlighted its role as a global...

Wondering whether Nestlé at around CHF 76.37 is priced for quality, or leaving some value on the table for patient shareholders? The stock is up 0.7% over the last week, while the 30 day return is a 9.1% decline and the one year return is a 12.3% decline, which may change how you think about both upside and risk. Recent coverage has focused on Nestlé's position as a global consumer staples giant, its broad portfolio of food and beverage brands, and how that scale influences investor...

Why Roche Holding (SWX:ROG) is in Focus After Its New Respiratory Test Launch Roche Holding (SWX:ROG) is back on investors radar after unveiling its cobas eplex respiratory pathogen panel 3, a multiplex test aimed at quickly identifying a wide range of respiratory viruses and bacteria from a single sample. See our latest analysis for Roche Holding. The new respiratory panel lands at a time when Roche Holding’s 1-month share price return of 10.47% decline contrasts with a 10.30% 1-year total...

Implenia AG ( VTX:IMPN ) stock is about to trade ex-dividend in three days. Typically, the ex-dividend date is two...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Recent share performance snapshot Sandoz Group (SWX:SDZ) has seen a mix of short term pressure and longer term strength, with a 0.3% decline over the past day, 0.5% over the past week and 16.5% over the past month, but a 3.2% gain over the past 3 months and a 62.6% total return over the past year. See our latest analysis for Sandoz Group. The recent 30 day share price return of 16.5% contrasts with a 62.6% total shareholder return over the past year. This suggests that earlier gains have...

Why Amrize Stock Is On Investors’ Radar Amrize (SWX:AMRZ) has drawn fresh attention after a recent share price pullback, with the stock showing a 12.7% decline over the past month and a 1.1% slip over the past 3 months. See our latest analysis for Amrize. The recent 12.7% 1 month share price return decline comes after a relatively mild 2.7% negative share price return year to date. This suggests that momentum has cooled rather than strengthened in the short term. If this pullback has you...

Edisun Power Europe (SWX:ESUN) has put out a mixed set of FY 2025 numbers, with first half revenue at CHF7.2 million and a basic EPS loss of CHF2.73, against a trailing twelve month picture that shows revenue of CHF50.9 million and basic EPS of CHF1.06. Over recent periods, revenue has moved between CHF7.8 million in 1H 2024 and CHF43.7 million in 2H 2024, while EPS has swung from a loss of CHF1.21 in 1H 2024 to EPS of CHF3.96 in 2H 2024, underlining just how volatile profitability has been...

GAM Holding (SWX:GAM) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 25.7 million and basic EPS of CHF 0.038 loss per share, while trailing 12 month figures to the same point show revenue of CHF 62.5 million and a basic EPS loss of CHF 0.100897. Over the past three reported halves, revenue has moved from CHF 43.9 million in 1H 2024 to CHF 37.7 million in 2H 2024 and then to CHF 25.7 million in 1H 2025, alongside basic EPS losses of CHF 0.248253, CHF 0.08653 and...

Nestlé is advancing the sale of its stake in its waters business, with private equity bidders moving forward in the process. The potential transaction is part of a broader effort to reshape the portfolio toward core areas such as coffee, pet food, nutrition, and food. The outcome of the bidding could influence how Nestlé allocates capital and manages its mix of brands in the coming years. For investors following SWX:NESN, this potential sale comes as the share price stands at CHF76.37, with...

Latest FY 2025 earnings snapshot Vaudoise Assurances Holding (SWX:VAHN) has just posted its FY 2025 numbers with first half revenue of CHF 777.1 million, basic EPS of CHF 28.89 and net income of CHF 84.1 million, alongside a combined ratio of 96.7%. Trailing 12 month figures show revenue of about CHF 1.5 billion, EPS of CHF 51.65 and net income of CHF 149.9 million. Over recent periods, revenue has moved from CHF 779.7 million in the first half of 2024 to CHF 777.1 million in the first half...

Amidst heightened uncertainty and inflation risks, European markets have experienced notable declines, with the pan-European STOXX Europe 600 Index falling by 3.79% due to geopolitical tensions and rising energy costs. In this environment, identifying undervalued stocks becomes particularly appealing as investors seek opportunities that may offer a margin of safety against market volatility.

UBS Global Wealth Management has adjusted its global asset allocation to a more defensive stance in response to ongoing geopolitical tensions, including the Iran conflict. The firm has shifted its regional views, moving India and the euro zone to neutral while upgrading Switzerland and European healthcare. These changes affect how UBS positions client portfolios in energy sensitive and risk exposed markets. For investors tracking UBS Group (SWX:UBSG), the latest positioning changes at its...

As you might know, Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) recently reported its annual numbers. It was a moderately...

Readers hoping to buy VZ Holding AG ( VTX:VZN ) for its dividend will need to make their move shortly, as the stock is...

Dividend and guidance draw attention to Medacta Group Medacta Group (SWX:MOVE) has attracted fresh investor interest after announcing an annual dividend of CHF 1.10 per share and issuing 2026 revenue growth guidance in a 10% to 14% range in constant currency. See our latest analysis for Medacta Group. The stock’s 1-day share price return of 1.62% contrasts with a weaker year-to-date share price return showing a 5.05% decline, while the 1-year total shareholder return of 14.85% points to...